First AD

Second AD

Roflumilast (Zoryve) is a phosphodiesterase-4 (PDE4) inhibitor approved for the treatment of plaque psoriasis. It works by reducing inflammation through the inhibition of PDE4, an enzyme involved in the inflammatory process. Roflumilast is available as a topical cream, providing a non-steroidal option for patients with mild to moderate plaque psoriasis. Its efficacy and safety profile have been demonstrated in clinical trials, showing significant improvement in psoriasis symptoms with a favorable side effect profile compared to traditional systemic therapies.

Guess the Therapy - October 22, 2025